Printer Friendly

Analysis of platelet eluate for the elucidation of sensitization to HLA in kidney transplant candidate/Analise do eluato de plaqueta para a elucidacao da sensibilizacao ao HLA em um candidato ao transplante de rim.

Introduction

Sensitization to human leukocyte antigens (HLA) in transplant immunology is the occurrence of alloantibodies in the serum of patients who desire to receive organs, directed towards HLA antigens. Sensitization in transplant candidates is normally associated to one or more risk factors such as previous transfusions, pregnancy or transplants (VONGWIWATANA et al., 2003; SOOSAY et al., 2003; MAO et al., 2007).

Alloantibodies cause graft destruction through several mechanisms such as complement activation and leukocyte recruitment (VONGWIWATANA et al., 2003). The need to identify sensitization against the donor's HLA antigens caused the standardization of routine crossmatch prior to any transplant. A positive crossmatch against T lymphocytes is an absolute contraindication against transplant owing to high hyper-acute rejection risks and to the association of chronic rejection (GEBEL et al., 2003). Systematic research of anti-HLA antibodies in receptor serum also provides important information on the receptor sensitization with regard to immunologically compatible organs (TERASAKI; CAI, 2008).

Sensitization to HLA antigens is normally determined by Panel Reactive Antibodies (PRA) which evaluate serum reactivity against the lymphocyte panel of known HLA specificity. The best PRA interpretation is provided by the patient's epidemiological information with regard to risk factors for anti-HLA alloantibodies formation (multiple pregnancy, poly-transfusion and re-transplants) (HYUN et al., 2012; MISHRA; BALIGA, et al., 2013).

A well-known standard method for research in anti-HLA antibodies consists of the reaction of complement-dependent cytotoxicity (CDC) which detects complement fixers antibodies IgM and IgG. They may be directed against HLA and non-HLA molecules (TERASAKI, McCLELLAND, 1964; PENA et al., 2013). The CDC method may be restricted by its inability to detect low antibody rates associated to transplanted organ rejection (GEBEL et al., 2003).

New techniques for the detection of anti-HLA antibodies, such as flow cytometry, ELISA and LABScreen, have recently been introduced in routine protocols in histocompatibility laboratories (ZEEVI et al., 2006; COLOMBO et al., 2007). Comparative studies on different methodologies showed great improvement in sensitivity by new techniques with regard to the standard cytotoxic method (ALTERMANN et al., 2006; KOZMA; BOHATY, 2007; LEE; OZAWA, 2007; LEE et al., 2009; HO et al., 2008; CERVELLI et al., 2013). However, improvement in sensitivity may cause discrepant results among the available methodologies. It is thus necessary to confirm anti-HLA antibodies detected only by immunoenzymatic methods (ELISA) which are employed in histocompatibility laboratories. Current study provides a case report of a kidney transplant candidate who denied a history of risk factors for HLA antigens sensitization. However, the patient's serum provided 32% PRA with specificity for HLAA2 antibodies detected by ELISA. Antibody adsorption method by platelets and the study of eluate were suggested to confirm results (MUELLER-ECKHARDT et al., 1972).

Material and methods Case report

The serum of a 42-year-old male patient on the waiting list for deceased-donor renal transplantation revealed anti-HLA-A2 antibodies which were detected by ELISA during routine research for anti-HLA antibodies. The patient denied any transfusion or transplant. Crossmatch proved negative by CDC and CDC with anti-human globulin (CDC-AHG) with a four-cell panel with positive typing for HLA-A2.

Discrepancies in results from ELISA and CDC-AHG methods and the patient's history of sensitization aired the hypothesis of a possible positive false result by ELISA. The patient's serum adsorption method with platelets and a study of the eluate as a confirmatory test were suggested to confirm the hypothesis.

Methodology

Suspension of platelets:

Platelets were obtained from 5 mL periphery blood with anticoagulant ethylenediaminetetraacetic acid (EDTA) (Vacutainer; Becton and Dickson, Oxford UK) from a serum-type HLA-A2 donor. After centrifugation at 1500 rpm for 10 min for platelet-rich plasma, the supernatant was transferred to a new tube and centrifuged at 3000 rpm for five minutes. The supernatant was removed and platelets were washed twice with PBS/EDTA buffer and final concentration adjusted for 1 x [10.sup.6] platelets m[L.sup.-1].

Adsorption of Antibodies:

Suspension of platelets was incubated with 500 [micro]L serum under analysis, during 60 min., at 22[degrees]C. After two washings and centrifuges at 3000 rpm, the final volume was adjusted to 300 [micro]L with PBS.

Elution of Antibodies:

Suspension of adsorbed platelets was acidified with HCl 10 N up to pH 3.0 during 10 minutes and then neutralized with NaOH 10 N. The supernatant with eluted antibodies was separated for analysis after being centrifuged at 3000 rpm.

Study on adsorbed serum with platelets and on the eluate of adsorbed platelets:

The two materials were submitted to research protocols for anti-HLA antibody by ELISA LAT1240 (One Lambda, Inc., Canoga Park, CA, USA), according to instructions by manufacturer. Samples were diluted in a diluting solution provided by the kit and incubated at room temperature with pre-defined quantities of purified HLA antigens on wells in a Terasaki plate (One Lambda, Inc., Canoga Park, CA, USA). Specific binding between an antibody in the test sample and any antigens in the plate would be detected by a subsequent incubation, at room temperature, with a human AntiIgG/alkaline phosphatase set, followed by an incubation at 36[degrees]C with BCIP (5-Bromo-4-chloro-3-indolyl-phosphate). Whereas the substrate becomes bluish in the presence of the set bound to the specific anti-HLA antibody, in its absence the set is removed at the washing stage and the substrate remains colorless. Spectrophotometric interpretation by a 630 nm wave length determines the presence or absence of anti-HLA antibodies by comparison with a cutoff. Statistic analysis determines the specificity of the detected antibody.

Ethics

Current study was approved by the Committee for Ethics in Research of the Universidade Estadual de Maringa (Protocol n. 192/2011).

Results and discussion

Kidney transplantion is an option for the treatment of end-stage renal disease (GARCIA et al., 2012). Donor-specific antibodies in the serum of patients who should receive kidney transplants are an important risk factor (GEBEL et al., 2003). Patients may develop an immune response subsequent to blood transfusions (SCORNIK, MEIER-KRIESCHE, 2011; BALASUBRAMANIAM et al., 2012; TANHEHCO; BERNS, 2012, YABU et al., 2013) due to HLA alloantibodies produced as a response to HLA alloantigens (HENDRICKSON; HILLYER, 2009; SCORNIK, MEIER-KRIESCHE, 2011). Consequently, it is highly difficult to find a donor with compatible organs because of the above alloimmunization (RODEY, 2003).

The omission of information (such as blood transfusion) by the organ recipient may cause ambiguous interpretations in laboratory results. The person accountable for these analyses should pay attention to this fact. Register of the above case is of paramount importance to histocompatibility professionals and, from the immunological point of view, to those responsible for the patient's admission for transplant.

Limitations of the CDC method in the detection of low antibody rates and the introduction of more sensitive techniques for the detection of anti-HLA antibodies have led to different results which frequently need confirmatory tests (WU et al., 2013).

The development of the antibody elution method with HCl described above provides a decrease in HLA class I molecules from the platelets surface previously adsorbed by serum which, in current case, is immune from anti-HLA-A2 antibodies (KURATA et al,. 1989).

Table 1 shows results by ELISA (LAT1240-One Lambda INC) with immune serum, with and without adsorption of platelets, and eluate. Whereas non-adsorption serum was positive for anti-HLA-A2 antibodies up to dilution 1/64, serum with adsorption failed to react to anti-HLA-A2 antibodies. Data suggested that antibodies had been removed by specific bind with HLA-A2 antigens on the platelet surface. Current results corroborated those by Blumberg, 1984 (BLUMBERG et al., 1984) who eluted HLA-A2 and HLA-B7 antigens from platelets by elution with acid. Therefore, antigens originated from platelets through the adsorption of soluble HLA antigens in the blood. Other authors have described the partial loss of HLA antigens from the platelet surface by using chloroquine or acid treatment (KURATA et al., 1989; NEUMULLER et al, 1993).

Table 1 also shows that, since the eluate reveals the presence of anti-HLA-A2 antibodies recovered from absorbed platelets up to 1/8 dilution, the binding of antibodies on specific HLA platelets is proved.

According to results in Table 2, non-adsorbed serum reactive to molecule HLA-A2 in the ELISA method up to 1/64 dilution failed to have any reaction in the CDC-AHG method.

Results are consistent with the hypothesis that HLA-A2 antigens were adsorbed from the platelets' surface by acid elution. They also elucidate the difference in the sensitivity of CDC and ELISA methods to detect antibodies. When patient's data were re-analyzed, a previous transfusion to the test was confirmed. It had been omitted in the first report and may have been the probable source of HLA sensitization, specifically HLA-A2.

Conclusion

Adsorption of antibodies with platelets and eluate analysis contributed towards an evaluation of sensitivity between CDC-AHG and ELISA methods for the characterization of the antibody specificity under analysis. It also confirms a history of the patient's sensitization by a clarification of the report's inconsistency. Additional evaluations of the protocol should be performed so that its potential as a confirmatory test in discrepancy cases between different antibody characterization tests may be evaluated.

Doi: 10.4025/actascihealthsci.v37i2.22127

References

ALTERMANN, W. W.; SELIGER, B.; SEL, S.; WENDT, D.; SCHLAF, G. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA based HLA crossmatch procedure. Histology and Histopathology, v. 21, n. 10, p. 1115-1124, 2006.

BALASUBRAMANIAM, G. S.; MORRIS, M.; GUPTA, A.; MESA, I. R.; THURAISINGHAM, R.; ASHMAN, N. Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation, v. 93, n. 4, p. 418-422. 2012.

BLUMBERG, N.; MASEL, D.; MAYER, T.; HORAN, P.; HEAL, J. Removal of HLA-A,B antigens from platelets. Blood, v. 63, n. 2, p. 448-450, 1984.

CERVELLI, C.; PISANI, F.; AURELI, A.; AZZARONE, R.; SCIMITARRA, M.; BATTISTONI, C.; DI IULIO, B.; FRACASSI, D.; SCARNECCHIA, M. A.; FAMULARI, A.; PAPOLA, F. For Anti-HLA-Specific Donor Antibodies Detection by Flow Cytometry Cytotoxic Crossmatches Comparison of Methods. Transplantation Proceedings, v. 45, n. 7, p. 2761-2764, 2013.

COLOMBO, M. B.; HAWORTH, S. E.; POLI, F.; NOCCO, A.; PUGLISI, G.; INNOCENTE, A.; SERAFINI, M.; MESSA, P.; SCALAMOGNA, M. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry. Part B, Clinical Cytometry, v. 72, n. 6, p. 465-471, 2007.

GARCIA, G. G.; HARDEN, P.; CHAPMAN, J. World Kidney Day Steering Committee 2012. The global role of kidney transplantation. Kidney and Blood Pressure Research, v. 35, n. 5, p. 299-304, 2012.

GEBEL, H. M.; BRAY, R. A.; NICKERSON, P. Pretransplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. American Journal of Transplantation, v. 3, n. 12, p. 1488-1500, 2003.

HENDRICKSON, J. E.; HILLYER, C. D. Noninfectious serious hazards of transfusion. Anesthesia and Analgesia, v. 108, n. 3, p. 759-769, 2009.

HO, E. K.; VASILESCU, E. R.; COLOVAI, A. I.; STOKES, M. B.; HALLAR, M.; MARKOWITZ, G. S.; D'AGATI, V. D.; COHEN, D. J.; RATNER, L. E.; SUCIU-FOCA, N. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. Transplant Immunology, v. 20, n. 1-2, p. 61-67, 2008.

HYUN, J.; PARK, K. D.; YOO, Y.; LEE, B.; HAN, B. Y.; SONG, E. Y.; PARK, M. H. Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. Transplantation Proceedings, v. 44, n. 1, p. 222-225, 2012.

KOZMA, L.; BOHATY, I. HLA class I antibody screening and typing in the sera of dialyzed patients with CDC and ELISA techniques: association with graft survival. Orvosi Hetilap, v. 148, n. 12, p. 553-558, 2007.

KURATA, Y.; OSHIDA, M.; TAKE, H.; FURUBAYASHI, T.; NAKAO, H.; TOMIYAMA, Y.; KANAYAMA, Y.; NAGAO, N.; OKUBO, Y.; YONEZAWA, T. New approach to eliminate HLA class I antigens from platelet surface without cell damage: acid treatment at pH 3.0. Vox Sanguinis, v. 57, n. 3, p. 199-204, 1989.

LEE, P. C.; OZAWA, M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Clinical Transplants, p. 219-226, 2007.

LEE, P. C.; OZAWA, M.; HUNG ,C. J.; LIN, Y. J.; CHANG, S. S.; CHOU, T. C. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Transplantation Proceedings, v. 41, n. 1, p. 95-98, 2009.

MAO, Q.; TERASAKI, P. I.; CAI, J.; EL-AWAR, N.; REBELLATO, L. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation, v. 83, n. 1, p. 54-61, 2007.

MISHRA, M. N.; BALIGA, K. V. Significance of panel reactive antibodies in patients requiring kidney transplantation. Saudi Journal of Kidney Diseases and Transplantation, v. 24, n. 3, p. 495-499, 2013.

MUELLER-ECKHARDT, C.; HEINRICH, D.; ROTHENBERG, V. Studies on cross reactive HL-A antibodies by elution with platelets. Tissue Antigens, v. 2, n. 6, p. 436-446, 1972.

NEUMULLER, J.; T OHIDAST -AKRAD, M.; FISCHER, M.; MAYR, W. R. Influence of chloroquine or acid treatment of human platelets on the antigenicity of HLA and the 'thrombocyte-specific' glycoproteins Ia/IIa, IIb, and IIb/IIIa. Vox Sanguinis, v. 65, n. 3, p. 223-231, 1993.

PENA, J. R.; FITZPATRICK, D.; SAIDMAN, S. L. Complement-dependent cytotoxicity crossmatch. Methods in Molecular Biology, v. 1034, n. 2, p. 257-83, 2013.

RODEY, G. E. HLA and granulocyte antigens. In: HILLYER, C. D.; SILBERSTEIN, L. E.; NESS, P. M.; ANDERSON, K. C. (Ed.). Blood banking and transfusion medicine: basic principles and practice. Philadelphia: Churchill Livingstone, 2003. p. 81-94.

SCORNIK, J. C.; MEIER-KRIESCHE, H. U. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. American Journal of Transplantation, v. 11, n. 9, p. 1785-1791, 2011.

SOOSAY, A.; O'NEILL, D.; COUNIHAN, A.; HICKEY, D.; KEOGAN, M. Causes of sensitisation in patients awaiting renal transplantation in Ireland. Irish Medical Journal, v. 96, n. 4, p. 109-112, 2003.

TANHEHCO, Y. C.; BERNS, J. S. Red blood cell transfusion risks in patients with end-stage renal disease. Seminars in Dialysis, v. 25, n. 5, p. 539-544, 2012.

TERASAKI, P. I.; CAI, J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation, v. 86, n. 3, p. 377-383, 2008.

TERASAKI, P. I.; McLELLAND, J. D. Microdroplet assay of human serum cytotoxins. Nature, v. 204, p. 998-1000, 1964.

VONGWIWATANA, A.; TASANARONG, A.; HIDALGO, L. G.; HALLORAN, P. F. The role of B cells and alloantibody in the host response to human organ allografts. Immunological Reviews, v. 196, n. 1, p. 197-218, 2003.

WU, P.; JIN, J.; EVERLY, M. J.; LIN, C.; TERASAKI, P. I.; CHEN, J. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Clinical Biochemistry, v. 46, n. 15, p. 1389-1393, 2013.

YABU, J. M.; ANDERSON, M. W.; KIM, D.; BRADBURY, B. D.; LOU, C. D.; PETERSEN, J.; ROSSERT, J.; CHERTOW, G. M.; TYAN, D. B. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrology, Dialysis, Transplantation, v. 28, n. 11, p. 2908-2918, 2013.

ZEEVI, A.; GIRNITA, A.; DUQUESNOY, R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunologic Research, v. 36, n. 1-3, p. 255-264, 2006.

Received on October 9, 2013.

Accepted on March 18, 2014.

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hugo Mendonca Mundim [1], Maria Aparecida Caixeta Lins [1], Eridane Botelho Guzman [1], Heline Leal Titan [1], Patricia Keiko Saito [2] and Sueli Donizete Borelli [2] *

[1] Fundacao Hemocentro de Brasilia, Brasilia, Distrito Federal, Brazil. [2] Universidade Estadual de Maringa, Av. Colombo, 5790, 87020-900, Maringa, Parana, Brazil. * Author for correspondence. E-mail: sueliborelli@gmail.com

Table 1. Result by ELISA method with patient's serum, with
and without adsorption, with platelets A2+ and the respective
eluate.

Dilution of   ELISA reaction with   ELISA reaction       ELISA
patient's     non-adsorbed serum         with        reaction with
serum           with platelets         adsorbed         eluate
                                      serum with
                                      platelets

Pure               Positive            Negative        Positive
1/2                Positive            Negative        Positive
1/4                Positive            Negative        Positive
1/8                Positive            Negative        Positive
1/16               Positive            Negative        Negative
1/32               Positive            Negative        Negative
1/64               Positive            Negative        Negative
1/128              Negative            Negative        Negative

Table 2. Result of the CDC-AHG method between the patient's
serum (non-adsorbed serum) with 4 different lymphocyte of
donors with HLA-A2.

Lymphocyte source   HLA-A phenotype   CDC-AHG results

Donor 1                 02, 68           Negative
Donor 2                 02, 30           Negative
Donor 3                 02, 11           Negative
Donor 4                 02, 33           Negative
COPYRIGHT 2015 Universidade Estadual de Maringa
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:texto en ingles
Author:Mundim, Hugo Mendonca; Lins, Maria Aparecida Caixeta; Guzman, Eridane Botelho; Titan, Heline Leal; S
Publication:Acta Scientiarum. Health Sciences (UEM)
Date:Jul 1, 2015
Words:2677
Previous Article:Influence of flexibility in the execution of movements in rhythmic gymnastics/Influencia da flexibilidade na execucao de movimentos da ginastica...
Next Article:Factors associated with consumption of fruits and vegetables by teenagers in Penha, Brazil/Fatores associados ao consumo de frutas e hortalicas em...
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters